Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072098 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
A Phase 1 study, sponsored by Max Sung.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00072098: Clinical Trial Phase 1 study, sponsored by Max Sung.
NCT00072098 is a Phase 1 study that was terminated before completion, run by Max Sung. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072098, a Phase 1 study, was terminated before completion, sponsored by Max Sung.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.
Primary Outcome
adverse event reporting
Interventions
- BIOLOGICAL interleukin-12 gene
- BIOLOGICAL adenovirus vector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2003-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Why NCT00072098 stopped before completion
NCT00072098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which interleukin-12 gene is the first listed.
NCT00072098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00072098 about?
NCT00072098 is a clinical study titled "Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer". RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases sec...
What is the current status of trial NCT00072098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2003-09. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00072098?
The interventions under investigation include: interleukin-12 gene (BIOLOGICAL), adenovirus vector (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072098?
This trial is sponsored by Max Sung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00072098's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia